Regeneron develops and commercializes Libtayo globally. About Immuneering Corporation Immuneering is a clinical-stage oncology company seeking to develop and commercialize more effective and ...

Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

impacting the company's revenue and profit margins. Despite these challenges, Regeneron's other drugs, particularly Dupixent and Libtayo, show promise for future growth and revenue generation.

The EC approved Libtayo – a fully human monoclonal antibody ... therapeutics for the treatment of cancer. Meanwhile, another company focused on advanced cervical cancer is Nykode Therapeutics ...

Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo. The company also announced a dividend for the first time.

The company also has an extremely full earlier ... Among oncology drugs, PD-1 antibody Libtayo is at the center, and is seeing solid growth (albeit from a smaller base) in niche indications ...

Furthermore, REGN’s diverse portfolio includes high-revenue medicines like Dupixent and Libtayo. The company also has a remarkably strong pipeline of late-stage candidates. Thus, I believe the ...

The company also has an extremely full earlier ... Among oncology drugs, PD-1 antibody Libtayo is at the center, and is seeing solid growth (albeit from a smaller base) in niche indications ...

The partners agreed to jointly fund a phase 2 trial of BNT111 and Libtayo. Each company retained full commercial rights to its molecule. The companies expanded the relationship to cover another ...

The company believes that, based on the regulatory strategy ... The investigation will determine whether administering low doses of THIO prior to Libtayo can enhance and prolong the immune response in ...